Avalo Therapeutics, Inc. 1Q 2026: Revenue ($19.7M), Net income ($19.63M), EPS ($0.98) — 10-Q Summary

Avalo Therapeutics, Inc. 1Q 2026: Revenue ($19.7M), Net income ($19.63M), EPS ($0.98) — 10-Q Summary — alphai